Company Information
Reneo Pharmaceuticals was founded on January 2014. The company is based in San Diego, CA, USA . The number of employees in Reneo Pharmaceuticals is less than 50. Reneo pharmaceuticals a clinical stage pharmaceutical companyFunding & investors
Reneo Pharmaceuticals has received 2 rounds of venture funding. The total funding amount is around $145M. Last venture funding round was $95M, announced on December, 2020.- New Enterprise Associates (NEA) (Venture capital)
- RiverVest (Venture capital)
- Pappas Capital (Venture capital)
- Lundbeckfonden Ventures (Venture capital)
- Abingworth (Venture capital)
- Contact us if you are interested to see all 11 investors
Similar Companies [beta]
Venture Categories
Active Venture Investors
- Active Investors in Biotechnology
- Active Investors in Health Care
- Active Investors in Science And Engineering
Venture Competitors
- Best Funded Biotechnology Startups
- Best Funded Health Care Startups
- Best Funded Science And Engineering Startups
News
Reneo Pharmaceuticals - Blog
- Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth
- Reneo Receives Orphan Drug Designations from the EMA for REN001 for the Treatment of LCHAD Deficiency and MELAS Syndrome and Moves Forward with Clinical Trials
- Restoring Cellular Power Outages: A New Drug Candidate to Treat Mitochondrial Disease
- Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001
- Reneo Pharmaceuticals Initiates Clinical Trial in McArdle Disease
- FDA Grants Orphan Drug Designation to Reneo Pharmaceuticals for REN001 for Treatment of Fatty Acid Oxidation Disorders
Gregory J. Flesher Appointed President and Chief Executive Officer SAN DIEGO, December 9, 2020 – Reneo Pharmaceuticals, Inc. today announced it raised $95 million in a Series B financing co-led by Novo Ventures and Abingworth and supported by existing investors New Enterprise Associates, RiverVest Venture Partners, Pappas Capital, and Lundbeckfonden Ventures, as well as… Continue reading Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and AbingworthThe post Reneo Pharmaceuticals Raises $95 Million in Series B Financing, Co-led by Novo Ventures and Abingworth appeared first on Reneopharma.
A global clinical trial is slated to begin for early next year to evaluate REN001 for the treatment of primary mitochondrial myopathies (PMM), including MELAS syndrome For LCHAD deficiency and other fatty acid oxidation disorders (FAOD), a Phase 1b clinical trial is currently recruiting and expanding globally and an international observational study is planned… Continue reading Reneo Receives Orphan Drug Designations from the EMA for REN001 for the Treatment of LCHAD Deficiency and MELAS Syndrome and Moves Forward with Clinical TrialsThe post Reneo Receives Orphan Drug Designations from the EMA for REN001 for the Treatment of LCHAD Deficiency and MELAS Syndrome and Moves Forward with Clinical Trials appeared first on Reneopharma.
A small biotech company is aiming to recharge tired cells, giving mitochondrial disease patients new hope of a disease-specific treatment. “We focus on patients, going after disease with high unmet needs, like primary mitochondrial myopathies,” Niall O’Donnell, Ph.D., President, CEO and Director of Reneo Pharmaceuticals, told BioSpace. https://www.biospace.com/article/restoring-cellular-power-outages-a-new-drug-to-treat-mitochondrial-diseases/ The post Restoring Cellular Power Outages: A New Drug Candidate to Treat Mitochondrial Disease appeared first on Reneopharma.
Recently completed clinical study is informing the design of a large, global PMM clinical trial, which is planned to begin early 2021; summary to be presented at UMDF Power Surge 2020 SAN DIEGO, June 23, 2020 – Reneo Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development… Continue reading Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001The post Reneo Pharmaceuticals Completes Clinical Study in Primary Mitochondrial Myopathies and Receives FDA Orphan Drug Designation for REN001 appeared first on Reneopharma.
San Diego – February 18, 2020 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has expanded its clinical development program for REN001, into glycogen storage disease type V (GSD V), also known as McArdle disease. The company is currently recruiting participants into a Phase 1b clinical trial in the United Kingdom… Continue reading Reneo Pharmaceuticals Initiates Clinical Trial in McArdle DiseaseThe post Reneo Pharmaceuticals Initiates Clinical Trial in McArdle Disease appeared first on Reneopharma.
San Diego – September 20, 2019 – Reneo Pharmaceuticals, a clinical stage pharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development has granted Orphan Drug Designation to the company’s lead drug candidate, REN001, for the treatment of fatty acid oxidation disorders (FAOD). “There is a pressing… Continue reading FDA Grants Orphan Drug Designation to Reneo Pharmaceuticals for REN001 for Treatment of Fatty Acid Oxidation DisordersThe post FDA Grants Orphan Drug Designation to Reneo Pharmaceuticals for REN001 for Treatment of Fatty Acid Oxidation Disorders appeared first on Reneopharma.
Share:
